Finance

Lists
Why is SCNI down 2,22%?
Dive Deeper
SCNI:NASDAQ
Scinai Immunotherapeutics Ltd - ADR
0,44 $
-2,22%
(-0,0100) 1D
0,43 $
-2,27% (-0,010)
After hours
Closed: 6 қар., 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SCNI...
Open
0,45 $
High
0,49 $
Low
0,43 $
Mkt. cap
1,34 млн
Avg. vol.
2,32 млн
Volume
13,13 мың
52-wk high
13,00 $
52-wk low
0,39 $
EPS
-2,80 $
Beta
2,27
Shares outstanding
706,59 м.
No. of employees
45
Open
0,45 $
High
0,49 $
Low
0,43 $
Mkt. cap
1,34 млн
Avg. vol.
2,32 млн
Volume
13,13 мың
52-wk high
13,00 $
52-wk low
0,39 $
EPS
-2,80 $
Beta
2,27
Shares outstanding
706,59 м.
No. of employees
45
News stories
From web sources and news partners
Profile
BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases. In collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen, both in Germany, BiondVax develops nanosized antibody therapies for diseases such as COVID-19, asthma and psoriasis. Wikipedia
About Scinai Immunotherapeutics Ltd - ADR
CEO-
Employees45
Founded2003 ж. 01 қаң.
Headquarters-
SectorHealth Care
Industry-
Websitescinai.com
Analyst
Recommendation
Action
Price target
Projected
Date
No analyst ratings found.
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
269,00 м.
269,00 м.
489,00 м.
460,00 м.
Cost of goods sold
960,00 м.
960,00 м.
1,61 млн
1,71 млн
Cost of revenue
960,00 м.
960,00 м.
1,61 млн
1,71 млн
Research and development expenses
566,00 м.
566,00 м.
628,00 м.
211,00 м.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
632,50 м.
632,50 м.
721,00 м.
683,00 м.
Operating expense
1,20 млн
1,20 млн
1,35 млн
894,00 м.
Total operating expenses
2,16 млн
2,16 млн
2,96 млн
2,61 млн
Operating income
-1,89 млн
-1,89 млн
-2,47 млн
-2,15 млн
Other non operating income
-3,50 мың
-3,50 мың
-
-
EBT including unusual items
-2,09 млн
-2,09 млн
3,58 млн
-2,00 млн
EBT excluding unusual items
-2,09 млн
-2,09 млн
-2,58 млн
-2,25 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-2,09 млн
-2,09 млн
3,58 млн
-2,00 млн
Net profit margin
-775,65%
-775,65%
731,49%
-435,43%
Earnings per share
-
-
-
-
Interest and investment income
16,00 мың
16,00 мың
-
-
Interest expense
-
-
-112,00 м.
-102,00 м.
Net interest expenses
16,00 мың
16,00 мың
-112,00 м.
-102,00 м.
Depreciation and amortization charges
-
-
-
-
EBITDA
-1,53 млн
-1,53 млн
-2,01 млн
-1,56 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google қолданбалары